

1000457

**510(K) SUMMARY**  
ARTHROCare CORPORATION  
OPUS SPEEDScrew SYSTEM

MAR 19 2010

**General Information**

**Submitter Name/Address:** ArthroCare Corporation  
680 Vaqueros Avenue  
Sunnyvale, CA 94085-3523

**Establishment Registration No.:** 2951580

**Contact Person:** Laura N. Kasperowicz  
Sr. Manager, Regulatory Affairs

**Date Prepared:** February 12, 2010

**Device Description**

**Trade Name:**

**Device Model Name:** Opus SpeedScrew System

**Generic/Common Name:** Bone Anchor

**Classification Name:** Screw, Fixation, Bone  
(Class II per 21 CFR 888.3040, Product code: HWC)

**Predicate Devices**

Opus SpeedScrew K081893 (Cleared October 1, 2008)

**Product Description**

The SpeedScrew Knotless Fixation Device is an implant that facilitates the attachment of tissue to bone. The SpeedScrew implant is a knotless fixation device, in other words surgical knots are not necessary for fixation of suture to tissue. The Opus SpeedScrew System consists of an implant and associated instruments for installation of the implant that is designed for specific indications in arthroscopic and orthopedic procedures.

**Indications For Use**

The SpeedScrew Knotless Fixation Device is indicated for use in fixation of soft tissue to bone. Examples of such procedures include:

**Shoulder:** Bankart Repair, SLAP lesion repair, acromio-clavicular separation, rotator cuff repair, capsule shift/capsule-labral reconstruction, biceps tenodesis and deltoid repair

**Ankle:** Lateral instability, medial instability, Achilles tendon repair/reconstruction and midfoot reconstruction

**Foot:** Hallux valgus reconstruction

**Elbow:** Tennis elbow repair, biceps tendon attachment

**Knee:** Extra-capsular repairs; reattachment of: medial collateral ligament, posterior oblique ligament or joint capsule closure to anterior proximal tibia; extra capsular reconstruction, ITB tenodesis; patellar ligament and tendon avulsions

## **510(k) SUMMARY**

### **Substantial Equivalence**

By definition, substantial equivalence means that a device has the same intended use and technical characteristics as the predicate device, or has the same intended use and different technological characteristics, but can be demonstrated to be as safe and effective as the predicate device. The SpeedScrew System design and technology is substantially equivalent to the existing SpeedScrew System cleared by the Food and Drug Administration (K081893). The differences between the SpeedScrew System and the predicate system do not raise questions regarding the safety and effectiveness of the implant. The proposed system, as designed, is as safe and effective as the predicate system.

### **Summary and Reason for 510k Notification**

For the purpose of this premarket notification [510(k)], ArthroCare proposes additional ancillary instrumentation to be used in conjunction with an existing bone anchor cleared under the trade name, Opus SpeedScrew Knotless Fixation Device originally cleared under K081893.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room -WO66-G609  
Silver Spring, MD 20993-0002

MAR 19 2010

ArthroCare Corporation  
% Ms. Laura N. Kasperowicz  
Sr. Manager, Regulatory Affairs  
680 Vaqueros Avenue  
Sunnyvale, California 94085-3523

Re: K100457

Trade Name: Opus SpeedScrew System  
Regulation Number: 21 CFR 888.3040  
Regulation Name: Smooth or threaded metallic bone fixation fastener  
Regulatory Class: Class II  
Product Code: HWC  
Dated: February 12, 2010  
Received: February 17, 2010

Dear Ms. Kasperowicz:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



Mark N. Melkerson  
Director  
Division of Surgical, Orthopedic,  
and Restorative Devices  
Office of Device Evaluation  
Center for Devices and  
Radiological Health

Enclosure

## INDICATIONS FOR USE STATEMENT

510(k) Number: K 100457

Device Name: Opus SpeedScrew System

Indications for Use:

The SpeedScrew Knotless Fixation Device is indicated for use in fixation of soft tissue to bone. Examples of such procedures include:

**Shoulder:** Bankart Repair, SLAP lesion repair, acromio-clavicular separation, rotator cuff repair, capsule shift/capsule-labral reconstruction, biceps tenodesis and deltoid repair

**Ankle:** Lateral instability, medial instability, Achilles tendon repair/reconstruction and midfoot reconstruction

**Foot:** Hallux valgus reconstruction


**Elbow:** Tennis elbow repair, biceps tendon attachment

**Knee:** Extra-capsular repairs; reattachment of: medial collateral ligament, posterior oblique ligament or joint capsule closure to anterior proximal tibia; extra capsular reconstruction, ITB tenodesis; patellar ligament and tendon avulsions

Prescription Use  AND/OR Over-The-Counter Use   
(Part 21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

  
(Division Sign-Off)  
Division of Surgical, Orthopedic,  
and Restorative Devices

510(k) Number K100457